These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue.
    Author: Bayoglu Tekin Y, Dilbaz B, Altinbas SK, Dilbaz S.
    Journal: Fertil Steril; 2011 Feb; 95(2):492-6. PubMed ID: 20883991.
    Abstract:
    OBJECTIVE: To compare efficacy of the levonorgestrel-releasing intrauterine system (LNG-IUS; Mirena) with depot GnRH analogue (GnRH-a; gosareline acetate; Zoladex) on endometriosis-related chronic pelvic pain (CPP) in patients with severe endometriosis during 12 months. DESIGN: Prospective, randomized, controlled study. SETTING: The reproductive endocrinology unit of a tertiary, research and education hospital. PATIENT(S): Forty women with severe endometriosis (revised The American Fertility Society [AFS] classification >40) and endometriosis-related CPP and control groups were enrolled in the study. INTERVENTION(S): The patients were treated with either LNG-IUS (n = 20) or GnRH-a (n = 20). The GnRH-a dose was repeated every 4 weeks for 24 weeks. MAIN OUTCOME MEASURE(S): Scores of CPP were evaluated using a visual analogue scale (VAS) and total endometriosis severity profile (TESP). RESULT(S): The TESP score decreased in the LNG-IUS group at first, third, and sixth month follow-up visits, whereas at the 12th month follow-up visit, the TESP scores were increased to values similar to pretreatment values. Although the VAS score had no significant alteration during the follow-up period in the LNG-IUS group, the GnRH-a group showed a significant decrease in the VAS score and TESP score at the end of 1 year. The LNG-IUS treatment showed a lower patient satisfaction. CONCLUSION(S): Both treatment modalities showed comparable effectiveness in the treatment of CPP-related endometriosis.
    [Abstract] [Full Text] [Related] [New Search]